Top Abstract Purchase Related
Home
>
Node
>
Subnode

Utilization of recombinant activated factor VIi in a case of spontaneous massive haemothorax in a patient with Von Recklinghausen's disease

Radeschi, G.; Boris, E.F.; Sega, P.; Odetto, L.; Venturino, S.

Minerva Anestesiologica 73(4): 241-244

2007

ISSN/ISBN: 0375-9393
PMID: 17380102
Document Number: 612686
Spontaneous haemothorax is a rare and often lethal complication of neurofibromatosis. Two kinds of vascular involvement are described: 1) stenotic or aneurysmatic modifications of large intrathoracic vessels, mainly treated with endovascular techniques; 2) dysplastic alterations in highly vascularized mesenchymal tumors. We describe a rare case of massive intrathoracic haemorrhage due to an upper mediastinic neurofibroma, successfully controlled with recombinant activated factor VII associated with surgical treatment.

Document emailed within 1 workday
Secure & encrypted payments

Beltrán de Heredia, S.; Bisbe, E.; Rojo, A.; Gracia, M.P.; López, M.; Escolano, F. 2008: Usefulness of activated recombinant factor VII for controlling massive bleeding: 4 years' experience in a university hospital Revista Espanola de Anestesiologia y Reanimacion 55(6): 355-359
Ho, C.; Ismail, A.R. 2014: Spontaneous haemothorax: a case report Medical Journal of Malaysia 69(5): 234-235
Vyhovs'ka, I.I.; Karol', I.S.; Fedak, L.M.; Tsytsyk, O.I. 2004: Use of recombinant activated factor VIi (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage Likars'ka Sprava 7: 77-81
Shamsi, T.Sultan.; Hossain, N.; Soomro, N.; Hasan, J.Ara.; Noorani, M.; Kazi, S.; Quraishy, M.Saeed.; Jameel, B.; Sultan, S.Tipu.; Haider, S. 2005: Use of recombinant factor VIIa for massive postpartum haemhorrage: case series and review of literature Jpma. Journal of the Pakistan Medical Association 55(11): 512-515
Guillet, B.; Pinganaud, C.; Proulle, V.; Dreyfus, M.; Lambert, T. 2002: Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VIi Thrombosis and Haemostasis 88(4): 698-699
Devecioğlu, O.; Unüvar, A.şe.ül.; Anak, S.; Bilge, I.; Ander, H.; Ziylan, O. 2003: Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VIi and platelet transfusions Turkish Journal of Pediatrics 45(1): 64-66
He, W.J.; Hu, Y.; Zhang, X.P.; Hong, M.; Guo, T.; Wei, W.N.; Song, S.J. 2008: Activated protein C ratio, plasma tissue factor activity and activated factor VIi in Chinese patients with coronary heart disease European Journal of Medical Research 13(2): 47-51
Kącka, K.; Kącki, W.; Merak, J.; Błęka, A. 2010: Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report Ortopedia, Traumatologia, Rehabilitacja 12(5): 448-458
Nagano, Y.; Nanko, M.; Nagahori, Y. 2000: Presacral malignant peripheral nerve sheath tumor in a patient with von Recklinghausen disease: case report Nihon Geka Gakkai Zasshi 101(5): 429-432
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Grochova, M.; Kalnasova, B.; Firment, J.; Olejarova, I.; Roland, R.; Lazurova, I. 2011: Pulmonary administration of activated recombinant factor VIi Bratislavske Lekarske Listy 112(1): 29-33
Sakorafas, G.H.; Giannopoulos, G.A.; Parasi, A.; Konstantoudakis, G.; Tzanakis, N.; Stergiopoulos, S.; Peros, G. 2008: Large somatostatin-producing endocrine carcinoma of the ampulla of vater in association with GIST in a patient with von Recklinghausen's disease. Case report and review of the literature JOP: Journal of the pancreas 9(5): 633-639
Bandyopadhyay, S.K.; Nandy, A.; Sarkar, S.; Ghoshal, A.G. 2008: Massive haemothorax: a presentation of pulmonary arteriovenous malformation Indian Journal of Chest Diseases and Allied Sciences 50(3): 285-287
Ingerslev, J.; Thykjaer, H.; Kudsk Jensen, O.; Fredberg, U. 1998: Home treatment with recombinant activated factor VII: results from one centre Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S107-S110
Pajares, A.; Larrea, L. 2006: Activated recombinant factor VII for bleeding after a kidney transplant: reflections Revista Espanola de Anestesiologia y Reanimacion 53(4): 266-7; author reply 268
Grinţescu, I.; Tulbure, D.; Mirea, L. 2006: Activated recombinant factor VIi (Novoseven) in multiple trauma patients: an outcome analysis Chirurgia 101(6): 615-624
Galstian, G.M.; Kolosova, I.V. 2014: Using recombinant activated blood coagulation factor VIi for treatment of hemorrhagic syndrome in patients with thrombocytopenia Anesteziologiia i Reanimatologiia 59(6): 60-66
Tanchev, S.; Platikanov, V.; Markova, S.; Slavov, N.; Bogdanova, A.; Dimitrova, D. 2004: Use of recombinant factor VIIa for the control of massive bleeding caused by uterine hypotonia in post-placental period Akusherstvo i Ginekologiia 43(1): 16-20
van Vroonhoven, T.J. 1970: A duodenal tumor in a patient with Von Recklinghausen's disease Minerva Medica 61: 1291-1294
Skalski, J.H.; Czapla, J.; Nadziakiewicz, Pł.; Kaczmarski, J.; Zembala, M. 2002: New possibilities in the postoperative measures to prevent bleeding in cardiac surgery. Will the recombinant activated factor VII improve surgical results? Przeglad Lekarski 59(11): 941-945